August 2026 Research Update

This month, several studies looked at ways to detect ATTRv-related organ involvement earlier or with less invasive testing, and the overall message was that no single test is enough. Heart imaging, eye-surface nerve imaging, nerve ultrasound, stomach biopsies, and computer models each captured different pieces of the picture, and mismatches between tests were common. For patients, this reinforces that ATTRv can show up in different organs and that screening often works best as a combination of tools rather than a single pass/fail result. [1] [2] [3] [4] [5]

For the heart, one screening study in variant carriers found that a common echocardiogram measurement called LV-GLS (a way to measure subtle squeeze changes) was often abnormal when bone scintigraphy was positive, but it was also abnormal in some people with a negative scan. The study described LV-GLS as giving complementary information to bone scintigraphy, meaning the two tests do not always agree and may flag different stages or patterns of change. This matters because it highlights why a "normal" or "abnormal" result on one heart test may not fully settle the question of early cardiac involvement. [1]

For nerve involvement, a corneal confocal microscopy study (a noninvasive scan of small nerves on the surface of the eye) reported clear differences between ATTRv-PN patients and healthy controls, and it also found abnormalities in presymptomatic carriers. Some corneal nerve measures tracked with nerve fiber density from sural nerve biopsies, but the corneal measures did not clearly separate milder from more advanced stages in this cross-sectional snapshot. In plain language, this suggests an eye-based nerve scan may be able to detect early nerve changes, but it is not yet proven to track day-to-day symptoms or stage in a reliable way. [2]

For common focal nerve problems, a small retrospective study in symptomatic ATTRv compared median nerve ultrasound at the wrist with nerve conduction studies for carpal tunnel-like involvement. Nerve conduction studies detected wrist involvement in all tested wrists, while ultrasound detected it in most but not all, and the ultrasound nerve size did not line up well with how severe the problem looked on electrical testing. This suggests ultrasound may be a helpful add-on when a less invasive look is wanted, but it did not replace standard nerve testing in this dataset. [3]

For stomach and gut involvement, one larger retrospective study comparing people with GI ATTRv amyloidosis to matched controls reported that routine endoscopy often looked normal, even when amyloid was present on tissue sampling. It also reported gastric food residue was more common in ATTRv, which the authors linked to slowed stomach movement, even without obvious visual abnormalities during the scope. For patients with GI symptoms, this helps explain why symptoms can occur even when the endoscopy report does not list clear abnormalities. [4]

A separate retrospective study used machine learning on a large genetic-testing cohort and reported that a model could flag key "red flags" such as bilateral carpal tunnel syndrome, ataxia, and family history of neuropathy when predicting who would test positive for a TTR mutation. The study also noted that the model needs outside testing before it could be trusted broadly, and that some inputs may reflect later-stage confirmatory testing rather than early signs. In everyday terms, this is an early attempt to formalize the pattern-recognition many families already notice, but it is not yet a tool used in routine care. [5]

Taken together, these studies mainly add understanding about how ATTRv may be detected and tracked, rather than changing what patients should do right now. The clearest near-term implication is that different tests can disagree, and that a single normal test may not fully rule out early involvement, especially in screening settings. What remains uncertain is which of these newer approaches best predicts future symptoms or progression, because most results were cross-sectional or retrospective rather than long-term follow-up. For patients and caregivers, this month supports the idea that monitoring often involves multiple organ-focused checks (heart, nerves, and sometimes GI), and that research is still working out which simpler or less invasive tests can reliably stand in for more involved evaluations. [1] [2] [3] [4] [5]

One larger real-world cohort study this month clarified how peripheral neuropathy can show up and evolve in Val122Ile ATTR amyloidosis. The study described neuropathy as common at disease onset and sometimes the only manifestation, while also showing that many people eventually developed both nerve and heart involvement over follow-up. For patients, this provides a clearer picture that symptom pathways can start in different places, and that the pattern can shift over time. [6]

In this Brazilian multicenter retrospective cohort, carpal tunnel syndrome often occurred before other signs, and nerve testing frequently showed abnormalities even when presentations varied. The report also described autonomic symptoms (such as blood pressure-related dizziness and GI symptoms) as common among those with neuropathy, and noted that mixed heart-and-nerve involvement increased over time in the followed group. This matters because it helps families understand why some people first notice hand/wrist problems, others notice sensory symptoms, and others start with heart concerns, even within the same variant. [6]

This evidence is based on retrospective routine-care data from a specific population, so it may not match every family or every variant, but it helps set expectations for how Val122Ile ATTR can present. It may matter now in the sense that it names common early experiences (especially carpal tunnel symptoms and neuropathy) and shows that autonomic symptoms can be part of the nerve picture, not a separate issue. What remains uncertain is how much these patterns depend on referral pathways and testing differences across centers, and how they compare to other variants outside Brazil. For patients and caregivers, the main value this month is a more grounded description of how nerve symptoms and heart involvement can overlap and change over time in Val122Ile disease. [6]

This month added information about ATTRv treatments in two different ways: how a newer gene-silencing drug behaves in the body, and how experts summarize the current treatment landscape for polyneuropathy. The treatment story was consistent in emphasizing modern silencers for ATTRv-PN, while also being clear that current approved disease-modifying therapies are not expected to meaningfully address central nervous system (CNS) involvement because of blood-brain barrier limits. For patients, the practical takeaway is that treatment evidence is strongest for peripheral nerve disease, while CNS disease remains a major unmet area. [7] [8]

An integrated clinical pharmacology analysis reported that monthly subcutaneous eplontersen (a gene-silencing antisense drug designed to lower transthyretin production) produced substantial reductions in blood TTR levels at steady state. It also reported that body weight noticeably changed drug levels (lower in heavier people), but neither weight nor other factors meaningfully changed TTR lowering, so no dose adjustment was needed, and that anti-drug antibodies were seen but did not meaningfully change TTR lowering or overall safety in the analyzed studies. In plain language, this strengthens confidence that the medication can deliver a fairly consistent biological effect across studied groups, although this paper focused on pharmacology rather than long-term outcomes in every subgroup. [7]

A German expert consensus statement recommended first-line treatment of symptomatic ATTRv polyneuropathy with vutrisiran or eplontersen, and discussed monitoring and switching when progression occurs. It also stated there is no evidence that switching between silencers is beneficial, and emphasized that none of the approved disease-modifying therapies is expected to provide meaningful CNS stabilization. For patients, this is a snapshot of how one national expert group weighs available trial data and practical considerations, rather than new head-to-head evidence. [8]

These publications may matter now mainly by clarifying expectations and the scope of what current disease-modifying therapies are designed to do. The eplontersen analysis strengthens the "how it works in the body" evidence and supports that TTR lowering and safety signals looked consistent in the included studies, but it is not a new results report comparing patient outcomes across different drugs. The German consensus can help patients understand how experts currently think about treatment choices for ATTRv-PN in Germany, but it reflects a structured interpretation of existing evidence, not new proof that one option is best for every person. A key uncertainty that remains is how to prevent or slow ATTRv-related CNS disease, because both the consensus statement and this month’s case report literature highlight the limits of current therapies for CNS involvement. [7] [8]

This month’s case reports and exploratory biology studies broadened what ATTRv can look like and why symptoms may differ across people. The case reports showed that ATTRv can present with atypical symptoms like hoarseness and cough, and that leptomeningeal (CNS lining) involvement may progress despite a CNS-penetrant stabilizer in a single long follow-up. Meanwhile, biopsy-based structural work and stomach-nerve studies aimed to explain disease variation at a tissue level, which is promising for research but not yet something most patients will encounter in routine care. [9] [10] [11] [12]

In one case, a man with the TTR Ala117Ser variant developed neuropathy symptoms along with hoarseness and chronic cough, and heart imaging plus genetic testing supported an ATTRv diagnosis with mixed nerve and possible heart involvement. The report emphasized that unusual respiratory or voice symptoms could slow recognition of the condition, especially when standard throat and chest exams do not show an obvious cause. For families, the main message is that ATTRv symptoms can be non-classic, and diagnosis may rely on connecting symptoms across body systems. [9]

A separate single-patient report followed a woman with the TTR p.Ala45Thr variant and leptomeningeal CNS involvement for 5 years while she took tolcapone (a transthyretin stabilizer that can reach the CNS). The patient had progressive neurologic and cognitive decline with worsening changes on spinal and brain imaging, even though tolcapone was described as well tolerated without liver toxicity in this case. In plain language, this case underscores that CNS ATTRv can be hard to control and that careful multi-test monitoring may be used to track it, but one person’s course cannot predict what will happen for others. [10]

A cryo-EM study of patient-derived amyloid fibrils reported that deposits could be mostly mutant transthyretin, mostly normal (wild-type) transthyretin, or a mix, and that earlier onset tended to align with mutant-dominant or mixed deposits in several cases. The authors presented a workflow to classify fibrils from biopsies, aiming to connect "what the amyloid is made of" to how disease begins. For patients, this is early-stage research that may eventually help explain why age of onset and organ patterns differ, but it does not yet guide personal decisions. [11]

Another study combined human stomach biopsies with a mouse model and reported that most ATTRv-PN patients had TTR amyloid in the stomach lining, along with reduced stomach-nerve density that tracked with gastroparesis and reflux severity. The same work linked certain gut bacteria patterns and histidine levels with stomach-nerve density, and found histidine supported nerve growth in lab assays. This adds a possible biological explanation for GI dysmotility symptoms and points to potential future biomarkers, but it does not show that changing diet or microbiome would change symptoms. [12]

These reports matter most for understanding the range of ATTRv experiences and where research is headed, rather than providing new proven options. The case reports may help patients feel less alone when symptoms are unusual (like hoarseness or cough) or when CNS involvement behaves differently from peripheral neuropathy, but single cases cannot establish what is typical. The biology studies add plausible explanations for why onset age, organ involvement, and GI symptoms vary, and they introduce biopsy-based and stomach-nerve measures that could become research biomarkers. What remains uncertain is how these lab and tissue findings translate into better prediction or treatment for an individual person, since these approaches are still early and not widely used in routine care. [9] [10] [11] [12]